Acumen pharmaceuticals secures $50.0 million credit facility with k2 healthventures

Charlottesville, va., nov. 13, 2023 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos) (“acumen” or the “company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (“aΒos”) for the treatment of alzheimer's disease (“ad”), today announced that it has entered into a senior secured loan and security agreement (the “loan agreement”) with k2 healthventures, a healthcare-focused specialty finance company.
ABOS Ratings Summary
ABOS Quant Ranking